Vercirnon sodium
Cat. No.: IBDI-437648
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively.
Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution
Online Inquiry
Product Details
Target |
CCR |
Molecular Weight |
466.91 |
Appearance |
Solid |
Synonyms |
GSK-1605786 sodium, CCX282-B sodium, Traficet-EN sodium |
SMILES |
O=S(C1=CC=C(C(C)(C)C)C=C1)([N-]C2=CC=C(Cl)C=C2C(C3=CC=[N+]([O-])C=C3)=O)=O.[Na+] |
Purity |
98.76% |
Storage & Handling
Shipping |
Room temperature in continental US. May vary elsewhere. |
Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.